Using real-world data to inform the epidemiology of cardiometabolic conditions and their treatment among older adults with HIV

Active Grant Awarded Last action

Award ID
RF1AG099751
Recipient
Awarding agency
Obligated
$3,663,975

Award facts

Assistance listing
93.866 Aging Research
Completion date 5% complete
Place of performance
Newark, NJ 07107, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute on Aging, awarded Rutgers The State University of New Jersey, doing business as RBHS-School of Nursing, a grant totaling $3.663975 million on September 9, 2026. The award is Grant RF1AG099751 under Aging Research (CFDA 93.866), a program that supports biomedical, social, and behavioral research directed toward understanding the aging process.

The project, titled "Using Real-World Data to Inform the Epidemiology of Cardiometabolic Conditions and Their Treatment Among Older Adults with HIV," uses national U.S. Medicare data from 2008 to 2025, which contain longitudinal clinical records for 45,000 older people with HIV. The recipient will study the epidemiology of cardiometabolic conditions within that cohort, characterize clinical management with cardiometabolic medications, and establish a framework for studying the risks and benefits of those medications. Conditions addressed include type 2 diabetes, atrial fibrillation, atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction, and chronic kidney disease.

The obligated amount is $3.663975 million. The ultimate completion date is August 31, 2030. Place of performance is Newark, New Jersey 07107. The assistance type is Grant.

Description

Abstract
Advances in antiretroviral therapy (art) have prolonged the life expectancy of people living with HIV (PWH), resulting in a growing segment of older adults ≥65 years of age living with HIV. In the prior decade alone, the prevalence of HIV in older persons insured through US medicare has risen 3-fold - a trend likely to accelerate in the ensuing years. The gains made in reducing HIV-related mortality are increasingly offset by a rise in mortality from alternative modalities - particularly cardiometabolic conditions, such as type 2 diabetes (T2D), atrial fibrillation (AF), atherosclerotic cardiovascular diseases, heart failure with reduced ejection fraction, and chronic kidney disease. These risks are further compounded among older PWH due to physiological changes associated with aging. Consequently, given the synergistic triad of HIV, art, and aging, older PWH represent one of the highest risk groups for developing cardiometabolic conditions. Despite these elevated risks, older PWH are routinely excluded from trials of cardiometabolic therapies based on criteria of older age and HIV status, and are underrepresented in HIV cohorts, leading to a research GAP regarding the epidemiology, management, and treatment optimization of cardiometabolic risk in this highly vulnerable, understudied, and rapidly growing population. Using national US medicare data from 2008-2025, which contain longitudinal clinical records for ≥45,000 older PWH, this proposal will enhance our understanding of the epidemiology of cardiometabolic conditions within a cohort of older PWH, characterize clinical management with cardiometabolic medications, and establish a framework to study risks and benefits of cardiometabolic medications. The rationale of our proposal is that in the absence of relevant trials or cohort studies, well-conducted observational studies are required to generate the requisite evidence base to understand the epidemiology of cardiometabolic conditions, their therapeutic management and associated outcome. Aim 1 will delineate the epidemiology and estimate the excess risk of cardiometabolic conditions among older PWH, as well as examine the uptake of cardiometabolic therapies among older PWH. Aim 2 will identify key sociodemographic factors, clinical factors, and prescriber characteristics associated with the receipt of cardiometabolic drugs among older PWH. Aim 3 will use two case examples (T2D, AF) to establish a framework to study safety and effectiveness of cardiometabolic drugs in older PWH. Our central hypotheses are that older PWH have higher prevalence of cardiometabolic conditions, specific sociodemographic factors, clinical factors, and provider characteristics are associated with receipt of cardiometabolic-friendly therapies, and that the risks and benefits of cardiometabolic medications are altered in older PWH. This proposal has the potential to exert an immediate, but sustained, impact on the clinical care of older PWH, by generating actionable evidence to improve our understanding of cardiometabolic risks, barriers to treatment, and the selection of effective and safe cardiometabolic therapies.

Quick answers

Who received award RF1AG099751?

RF1AG099751 was awarded to Rutgers The State University Of New Jersey by National Institute on Aging (National Institutes of Health) on September 9, 2026.

How much is award RF1AG099751 worth?

$3,663,975 has been obligated on RF1AG099751.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award